['hepatitis c virus infection']
['simeprevir', 'simeprevir', 'sofosbuvir', 'sofosbuvir']

        Inclusion Criteria:

          -  Hepatitis C virus (HCV) genotype 1a or 1b infection confirmed before randomization

          -  Documentation of the presence or absence of a NS3 Q80K polymorphism in HCV genotype 1a
             infected participants before randomization

          -  Documentation of the IL28B genotype before randomization

          -  HCV ribonucleic acid level greater than 10,000 IU/mL at screening

          -  Treatment-experienced participants must have at least 1 documented previous course of
             interferon-based regimen with or without ribavirin

          -  Absence of cirrhosis in participants

        Exclusion Criteria:

          -  Evidence of clinical hepatic decompensation (history or current evidence of ascites,
             bleeding varices or hepatic encephalopathy)

          -  Infection/co-infection with HCV non-genotype 1a or 1b

          -  Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2)
             (positive HIV-1 or HIV-2 antibodies test at screening)

          -  Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen positive)

          -  Previously been treated with any direct acting anti-HCV agent (approved or
             investigational) for chronic HCV infection
      